ArticleDrug discovery today. Disease models2014
Development of Animal Models of Human IgA Nephropathy.
Article in Drug discovery today. Disease models, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Serum anti-β2 spectrin IgA antibodies are produced in a CD4 T cell-independent manner in IgA nephropathy model mouse.Frontiers in immunology · 2026Article
- B Cell Activating Factor Does Not Play a Pivotal Role in the Synthesis of Aberrantly Glycosylated IgA.Nephrology (Carlton, Vic.) · 2025Article
- Review
- Experimental models for preclinical research in kidney disease.Zoological research · 2024Review
- TNF-α-mediated podocyte injury via the apoptotic death receptor pathway in a mouse model of IgA nephropathy.Renal failure · 2022Article
- Efficacy of Traditional Chinese Medicine on Animal Model of IgA Nephropathy: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Autoimmune-mediated renal disease and hypertension.Clinical science (London, England : 1979) · 2021Review
- Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.Journal of autoimmunity · 2021Article
- Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.International journal of molecular sciences · 2021Review
- Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy.Frontiers in physiology · 2021Article
- Comparative proteomic analysis of renal proteins from IgA nephropathy model mice and control mice.Clinical and experimental nephrology · 2020Article
- Nephroprotective effect of losartan in IgA model rat.The Journal of international medical research · 2019Article
- Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.International journal of molecular sciences · 2019Article
- Endothelial cell-specific overexpression of endothelial nitric oxide synthase in Ins2Akita mice exacerbates diabetic nephropathy.Journal of diabetes and its complications · 2019Article
- The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model.International journal of molecular sciences · 2018Article
- Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy.Seminars in nephrology · 2018Review
- Kidney disease models: tools to identify mechanisms and potential therapeutic targets.Zoological research · 2018Review
- Primary IgA nephropathy: current challenges and future prospects.International journal of nephrology and renovascular disease · 2018Review
- Optimizing the translational value of animal models of glomerulonephritis: insights from recent murine prototypes.American journal of physiology. Renal physiology · 2016Review
- The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.Frontiers in immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis in the world. IgAN is characterized by the mesangial accumulation of immune complexes containing IgA1, usually with co-deposits of complement C3 and variable IgG and/or IgM. Although more than 40 years have passed since IgAN was first described, the mechanisms underlying the disease development are not fully understood. Small-animal experimental models of IgAN can be very helpful in studies of IgAN, but development of these models has been hindered by the fact that only humans and hominoid primates have IgA1 subclass. Thus, multiple models have been developed, that may be helpful in studies of some specific aspects of IgAN. These models include a spontaneous animal model of IgAN, the ddY mouse first reported in 1985. These mice show mild proteinuria without hematuria, and glomerular IgA deposits, with a highly variable incidence and degree of glomerular injury, due to the heterogeneous genetic background. To obtain a murine line consistently developing IgAN, we intercrossed an earlyonset group of ddY mice, in which the development of IgAN includes mesangial IgA deposits and glomerular injury. After selective intercrossing for >20 generations, we established a novel 100% early-onset grouped ddY murine model. All grouped ddY mice develop proteinuria within eight weeks of age. The grouped ddY mouse model can be a useful tool for analysis of multiple aspects of the pathogenesis of IgAN and may aid in assessment of some approaches for the treatment of IgAN.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.